French Pharmaceuticals & Biotech Strong Balance Sheet Stocks

Novacyt

Market Cap: €29.1m

Develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors.

Aelis Farma

Market Cap: €14.7m

A clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France.

Sanofi

Market Cap: €90.8b

Engages in the research, development, manufacture, and marketing of therapeutic solutions.

Ipsen

Market Cap: €12.8b

A biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally.

Vetoquinol

Market Cap: €800.8m

A veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region.

ABIVAX Société Anonyme

Market Cap: €6.7b

A clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.

Eurobio Scientific Société anonyme

Market Cap: €226.5m

Engages in the design, development, and commercialization of in vitro diagnostics products in the areas of transplantation, immunology, infectious diseases, life-science, and oncology.

Transgene

Market Cap: €206.5m

A biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France.

Eurofins-Cerep

Market Cap: €77.2m

Provides various drug discovery services to pharmaceutical, biopharmaceutical, and biotechnology companies France and internationally.

Cellectis

Market Cap: €195.3m

A clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.

DBV Technologies

Market Cap: €874.1m

A clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.

Sensorion

Market Cap: €128.4m

A biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France.

ABIONYX Pharma

Market Cap: €89.5m

A biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States.

Valbiotis

Market Cap: €20.8m

Engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia.

Boiron

Market Cap: €480.9m

Manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally.

Virbac

Market Cap: €2.8b

Manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, the United States, Brazil, and the Pacific.

Euroapi

Market Cap: €118.8m

Develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally.

genOway Société anonyme

Market Cap: €21.9m

A biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide.

Nicox

Market Cap: €31.9m

Operates as an ophthalmology company in France and internationally.

THX Pharma Société Anonyme

Market Cap: €54.4m

A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.

Plant Advanced Technologies

Market Cap: €7.6m

A plant biotechnology company, produces and sells actives for cosmetic, pharmaceutical, and agrochemical markets in France.

MaaT Pharma

Market Cap: €53.1m

A late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival.